PACIRA BIOSCIENCES, INC. Amortization of Debt Issuance Costs and Discounts
PACIRA BIOSCIENCES, INC. (PCRX) reported Amortization of Debt Issuance Costs and Discounts of $1.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $577.00K, a 33.83% decline year-over-year.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $577.00K, a 33.45% decline year-over-year.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-06-30 was $872.00K.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs and discounts for the quarter ending 2025-03-31 was $867.00K.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs and discounts for fiscal 2025 was $3.00M, a 6.98% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs and discounts for fiscal 2024 was $3.22M, a 14.03% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. amortization of debt issuance costs and discounts for fiscal 2023 was $3.75M.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|
| 2026-06-30 | $577.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.15M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $577.00K 10-Q · filed 2026-04-30 | ||
| 2025-12-31 | $3.00M 10-K · filed 2026-02-26 | ||
| 2025-06-30 | $872.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.74M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $867.00K 10-Q · filed 2026-04-30 | ||
| 2024-12-31 | $3.22M 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $3.75M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |